Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emma Loyfman

Optometrist Chicago, IL Doctor of Optometry

NPI 1174752091 CMS profile 189266

3144 N Broadway St, Chicago, IL 60657

Open in the dashboard

General payments

$22,690

187 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Emma Loyfman of Chicago, IL is reported in the CMS Open Payments database as having received $22,690 across 187 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,747 24
2024 General $4,748 36
2023 General $2,645 31
2022 General $5,837 29
2021 General $2,087 27
2020 General $715 18
2019 General $912 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emma Loyfman
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Emma Loyfman were reported at $5,747. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Emma Loyfman Optometrist median Middle half National median
2019 $912 $159 $67–$371 $163
2020 $715 $72 $29–$165 $114
2021 $2,087 $125 $46–$292 $132
2022 $5,837 $162 $66–$374 $149
2023 $2,645 $177 $72–$406 $160
2024 $4,748 $188 $77–$427 $164
2025 $5,747 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $17,853 82 payments
  2. Alcon Vision LLC $1,502 37 payments
  3. Bausch & Lomb Americas Inc. $1,351 25 payments
  4. Johnson & Johnson Vision Care, Inc. $1,129 25 payments
  5. Allergan Inc. $223 3 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $184 4 payments
  7. Sight Sciences, Inc. $122 3 payments
  8. Glaukos Corporation $115 1 payment
  9. AbbVie, Inc. $112 2 payments
  10. Ivantis, Inc $36 1 payment
  11. Other $62 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,675 10 payments
  2. Food and Beverage $8,325 169 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,500 2 payments
  4. Travel and Lodging $2,190 6 payments
Products named General payments · program years 2019–2025
  1. MyDay Contact Lens $6,795 56 payments
  2. Biofinity Contact Lens $3,115 3 payments
  3. CVI Contact Lens $1,701 6 payments
  4. Multiple Brands Contact Lens $1,227 5 payments
  5. INFUSE $927 17 payments
  6. Acuvue $763 19 payments
  7. DAILIES $522 16 payments
  8. TOTAL30 $469 10 payments
  9. MiSight Contact Lens $407 6 payments
  10. Precision 1 $371 9 payments
  11. Other $1,693 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

187 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record